{"filing":{"accession_number":"0001213900-26-093520","cik":"0001938571","ticker":"APTN","company_name":"ADAPTIN BIO, INC.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-20","primary_document":"ea0303128-8k_adaptin.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1938571/000121390026093520/ea0303128-8k_adaptin.htm"},"events":[{"id":29475,"run_id":26991,"accession_number":"0001213900-26-093520","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Adaptin Bio announced the opening of enrollment in a Phase 1 clinical trial for APTN-101, its proprietary BRiTE therapeutic for glioblastoma treatment. This represents a material operational and clinical development milestone—the transition from preclinical to first-in-human clinical testing—that would affect a reasonable investor's assessment of the company's pipeline progress and near-term value drivers. While not fitting a specific named event type, this is clearly an operational/strategic milestone in the company's drug development program.","company_name":"ADAPTIN BIO, INC.","ticker":"APTN","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31771,"accession_number":"0001213900-26-093520","item_number":"8.01","item_title":"OTHER EVENTS.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Adaptin Bio announced the opening of enrollment in a Phase 1 clinical trial for APTN-101, its proprietary BRiTE therapeutic for glioblastoma treatment. This represents a material operational and clinical development milestone—the transition from preclinical to first-in-human clinical testing—that would affect a reasonable investor's assessment of the company's pipeline progress and near-term value drivers. While not fitting a specific named event type, this is clearly an operational/strategic milestone in the company's drug development program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:13:56.371515+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31771,"accession_number":"0001213900-26-093520","item_number":"8.01","item_title":"OTHER EVENTS.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Adaptin Bio announced the opening of enrollment in a Phase 1 clinical trial for APTN-101, its proprietary BRiTE therapeutic for glioblastoma treatment. This represents a material operational and clinical development milestone—the transition from preclinical to first-in-human clinical testing—that would affect a reasonable investor's assessment of the company's pipeline progress and near-term value drivers. While not fitting a specific named event type, this is clearly an operational/strategic milestone in the company's drug development program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:13:56.371515+00:00","company_name":"ADAPTIN BIO, INC.","ticker":"APTN","filing_date":"2026-08-25"}]}